MM-121 studies in breast cancer models and xenograft response prediction. MM-111 breast cancer study in combination with trastuzumab.
Cambridge, MA (PRWEB) April 17, 2010 -- Merrimack Pharmaceuticals, Inc. announced today that it will present pre-clinical data on MM-121 and MM-111, the two lead candidates in the company’s pipeline of five novel cancer antibodies, at the 101st Annual Meeting of the American Association for Cancer Research (AACR) being held April 17 – 21, 2010, in Washington, D.C.
Two posters will show pre-clinical data on MM-121, a monoclonal antibody designed to block signaling of the ErbB3 receptor. The ErbB receptor family has been known for years to have an impact on cancer signaling. Merrimack gained insight into the critical role of the ErbB3 receptor in cancer biology through the use of their Network Biology platform that led to the novel design of MM-121.
Poster 1806 shows pre-clinical data on MM-121’s efficacy as a single agent, and in combination with tamoxifen and paclitaxel, in ER+ and triple negative breast cancer studies.
Title: Efficacy of MM-121 in ER+ and triple negative breast cancer studies
Poster Session: Clinical Research 7
Date/Time: Monday April 19, 2010 9:00 AM - 12:00 PM
Location: Exhibit Hall A-C, Poster Section 32 Permanent Abstract
Poster 3756 shows pre-clinical data on efforts to derive a predictive biomarker signature that identifies tumors responsive to MM-121.
Title: Prediction of xenograft response to MM-121, an anti-ErbB3 inhibitor, using computational modeling and measurements of five biomarkers
Poster Session: Clinical Research 13
Date/Time: Tuesday April 20, 2010 9:00 AM - 12:00 PM
Location: Exhibit Hall A-C, Poster Section 33
MM-111 is a bispec
Copyright©2010 Vocus, Inc.
All rights reserved